Jeffrey W. Albers
CIK 1638474 · CEO AND PRESIDENT · last filed 2026-05-29
Jeffrey W. Albers is a CEO AND PRESIDENT who has filed 93 SEC Form 4 insider transactions across 5 companies since 2015. The most recent filing, for SYRE, was dated May 29, 2026. Across all open-market trades the lifetime net is −$64.5M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $2.2M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$2.21M
5
93
-$64.49M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| SYRE | Director | 27,360 | $80.79 | $2.21M | -$257.2K | 6 | 2026-05-29 |
| KYMR | Director | 0 | $86.20 | $0 | -$1.80M | 12 | 2025-12-08 |
| Blueprint Medicines Corp (BPMC) Delisted | Director | 0 | $129.46 | $0 | -$62.43M | 69 | 2025-07-21 |
| Spyre Therapeutics, Inc. (AGLE) Delisted | Director | — | $12.01 | — | $0 | 1 | 2023-11-27 |
| Dianthus Therapeutics, Inc. /DE/ (MGTA) Delisted | Director | 4,152 | $11.19 | $46.5K | $0 | 5 | 2022-06-30 |
Recent Filings
93 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-05-29 | SYRE | Grant (A) | — | $0 | EDGAR |
| 2025-12-08 | KYMR | Mixed | — | -$377.9K | EDGAR |
| 2025-10-14 | KYMR | Mixed | — | -$244.2K | EDGAR |
| 2025-07-21 | Blueprint Medicines Corp (BPMC) Delisted | Mixed | −150,532 | $0 | EDGAR |
| 2025-06-26 | KYMR | Grant (A) | — | $0 | EDGAR |
| 2025-06-24 | Blueprint Medicines Corp (BPMC) Delisted | Grant (A) | +3,902 | $499.9K | EDGAR |
| 2025-06-03 | KYMR | Mixed | — | -$245.5K | EDGAR |
| 2025-06-02 | SYRE | Grant (A) | — | $0 | EDGAR |
| 2025-05-29 | Blueprint Medicines Corp (BPMC) Delisted | Mixed | — | -$325.4K | EDGAR |
| 2025-03-17 | Blueprint Medicines Corp (BPMC) Delisted | Sell (S) | −5,766 | -$512.0K | EDGAR |